CTSD is also considered to be a target in antibody-based therapy for the treatment of triple-negative breast cancer due to its correlation with poor prognosis of breast cancer and providing a tumor-specific extracellular target [73, 74]. The gene discussed is CTSD; the disease is triple-negative breast carcinoma.